Inspection Record

Prescription Lab Compounding Pharmacy — FDA 483 Findings

US FDAInspected 2015-10-16Published 2024-01-17 3 findingsAseptic processing and sterility assurance

Inspectors Caryn M. McnabThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

2Aseptic processing and sterility assurance

Specifically, Environmental monitoring <Redac tion (b)(4) (b)(4)> used to prepare sterile products is not conducted each day that sterile drugs are prepared.

3Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Prescription Lab Compounding Pharmacy company profile — full history US FDA documents, 2024 Go to Findings search